Kymera Therapeutics (KYMR) Leerink Global Healthcare Conference 2026 summary

Strategic focus and scientific approach

• Emphasis on targeted protein degradation to address undrugged targets with strong human genetic validation, particularly in immunology pathways.

• Shifted focus to immunology due to transformative impact of biologics in diseases like psoriasis, AD, IBD, and lupus.

• Aim to deliver biologics-like efficacy in an oral format, targeting intracellular proteins such as STAT6.

KT-621 program and clinical progress

• KT-621 demonstrated robust STAT6 degradation (94–98%) and efficacy in phase I-B, matching or exceeding upstream biologics in Type 2 inflammation and comorbidities.

• Phase II-B studies in AD (200 patients, 16 weeks + 52-week OLE) and asthma (12 weeks, FEV1 primary endpoint) are underway, with readouts expected in 2027.

• Both 100 mg and 200 mg doses showed similar efficacy and safety profiles in patients.

• Early data indicate strong interest and enrollment from investigators and patients.

Safety, differentiation, and biomarker insights

• Safety profile to date is placebo-like, supported by human genetics and preclinical chronic toxicity studies.

• No significant adverse events observed in early studies; ongoing trials will further define long-term safety.

• KT-621 showed significant reductions in FeNO (up to 56%) and robust effects on itch, SCORAD, and sleeplessness.

• Impact on IL-31 and pruritus is promising but requires further data for definitive claims.